Filing Details
- Accession Number:
- 0001209191-14-050013
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-08-01 18:52:36
- Reporting Period:
- 2014-07-30
- Filing Date:
- 2014-08-01
- Accepted Time:
- 2014-08-01 18:52:36
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1505512 | Regulus Therapeutics Inc. | "RGLS" | Pharmaceutical Preparations (2834) | 264738379 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1178670 | Alnylam Pharmaceuticals, Inc. | 300 Third Street, 3Rd Floor Cambridge MA 02142 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2014-07-30 | 1,000 | $6.60 | 6,110,800 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2014-07-31 | 1,750 | $6.42 | 6,109,050 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2014-08-01 | 2,600 | $6.21 | 6,106,450 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2014.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.46 to $6.74 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.34 to $6.61 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.14 to $6.36 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Billionaire Hedge Funds
